Solaxa Inc. Collaborates with National Ataxia Foundation
Bethesda, MD and Minneapolis, MN; September 25, 2024 – On International Ataxia Awareness Day, Solaxa Inc. announces the signing of a sponsored research agreement (SRA) with the National Ataxia Foundation (NAF) to pursue treatment options for patients with Spinocerebellar Ataxia Type 27B (SCA27b). Solaxa is collaborating with NAF as follows:
- Solaxa has joined the NAF Drug Development Collaborative (DDC), which launched in 2020 with the goal of accelerating the development of treatments for Ataxia.
- Solaxa is sponsoring the expansion of NAF’s ongoing natural history study, known as the Clinical Research Consortium for the Study of Cerebellar Ataxia (CRC-SCA), to include SCA27B.
- Solaxa is sponsoring a free genetic testing program, run by NAF, to facilitate a formal diagnosis of SCA27B, a disease that was first genetically confirmed and published in January 2023.
Solaxa’s Founder and Chief Executive Officer, Christian Walker, noted that “Solaxa is proud to support these important SRA initiatives, as we seek to develop new treatments for patients with Ataxia.”
Andrew Rosen, CEO of the National Ataxia Foundation, said that “we appreciate Solaxa’s support of these important initiatives and welcome their participation in the DDC, CRC-SCA, and genetic testing programs that lie at the core of NAF’s mission to lead the fight to accelerate the development of treatments and a cure while working to improve the lives of those living with Ataxia.”
About Solaxa
Solaxa is a clinical-stage biopharmaceutical company developing treatments that restore nerve function in patients with rare neurodegenerative diseases and acute nerve injuries. The company is developing a class of aminopyridine drugs that both detect and treat ion channel dysfunction. Solaxa’s public benefit mission is to advance scientific knowledge and deliver impactful and accessible therapies that improve outcomes for patients worldwide. For more information, visit Solaxa.com.
About National Ataxia Foundation
The National Ataxia Foundation (NAF) was established in 1957 to help persons with Ataxia and their families. NAF’s vision of a world without Ataxia will be accomplished through our primary programs of funding Ataxia research, providing vital programs and services for Ataxia families, and partnering with pharmaceutical companies in the search for treatments and a cure. We work closely with the world’s leading Ataxia researchers and clinicians, promoting exchanges of ideas and innovation in Ataxia discovery. For more information, visit Ataxia.org.
CONTACTS:
Luis Gutierrez, COO
Solaxa Inc.
Andrew Rosen, CEO
National Ataxia Foundation